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Abstract The time trade-off (TTO) valuation technique
is widely used to determine utility values of health out-
comes to inform quality-adjusted life-year (QALY) calcu-
lations for use in economic evaluation. Protocols for
implementing TTO vary in aspects such as the trade-off
framework, iteration procedure and its administration
model and method, training of respondents and inter-
viewers, and quality control of data collection. The most
widely studied and utilized TTO valuation protocols are the
Measurement and Valuation of Health (MVH) protocol, the
Paris protocol and the EuroQol Valuation Technology (EQ-
VT) protocol, all developed by members of the EuroQol
Group. The MVH protocol and its successor, the Paris
protocol, were developed for valuation of EQ-5D-3L health
states. Both protocols were designed for a trained inter-
viewer to elicit preferences from a respondent using the
conventional TTO framework with a fixed time horizon of
10 years and an iteration procedure combining bisection
and titration. Developed for valuation of EQ-5D-5L health
states, the EQ-VT protocol adopted a composite TTO
framework and made use of computer technology to
facilitate data collection. Training and monitoring of
interviewers and respondents is a pivotal component of the
EQ-VT protocol. Research is underway aiming to further
improve the EuroQol protocols, which form an important
basis for the current practice of health technology assess-
ment in many countries.
Key Points for Decision Makers
The time trade-off (TTO) technique has been widely
used to obtain health state values for use in the
economic evaluation of health technologies.
The use of different variants of TTO creates two
practical problems: incomparability across studies
and difficulty in choosing among the variants.
The EuroQol Group, a multi-disciplinary group of
researchers from all over the world, has developed
three standardized TTO-based protocols for
valuation of EQ-5D health states: the MVH protocol,
the Paris protocol and the EQ-VT protocol. For the
valuation of the 3-level version of the EQ-5D (EQ-
5D-3L), the Paris protocol is recommended. For the
valuation of the 5-level version of EQ-5D (EQ-5D-
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Quality-adjusted life years (QALYs), a generic measure of
health combining quality and length of life, are increas-
ingly used to quantify outcomes in the economic evaluation
of health technologies. According to the principles under-
pinning the QALY, the quality-of-life (QOL) weights, also
described as health state utility values, must lie on an
interval scale anchored at 0 (death) and 1 (full health) [1].
A second assumption underlying the basic QALY model is
that the QOL weight for a given health state does not
depend on how long it is experienced (constant propor-
tional time preference) [2].
A variety of survey-based methods can be used to esti-
mate these values based on the stated preferences of indi-
viduals of interest. Methods include standard gamble (SG),
time trade-off (TTO), visual analogue scale (VAS), ranking
exercises and, more recently, discrete-choice experiments
(DCEs) (see Ryan et al. [3] for a systematic review of
preference-elicitation techniques). Choice-based methods
are typically preferred by economists, since these reflect
the view that the value an individual places on something
should be estimated by what they would be willing to
forego to obtain it (or in the case on impaired health, in
order to avoid it). The SG technique, which is grounded in
expected utility theory, has traditionally been considered
the gold standard valuation method. However, in general,
people have difficulties assessing probabilities, but can
relate more easily to time [1]. Hence, an alternative tech-
nique—TTO [4]—has been widely used to value different
states of health. It has been shown that TTO and SG result
in different values and that the total bias in TTO valuation
is smaller than that in SG [5].
TTO can be implemented in numerous ways, although
the approach that comes closest to obtaining the unob-
servable true utilities cannot be known. Over the last
decades, a growing number of different variants of TTO
have been used, which creates two practical problems:
incomparability across studies and difficulty in choosing
between the variants. Studies have shown that the design of
the TTO task influences how respondents value health [6].
Therefore, values from studies using different TTO tasks
may not be comparable [7]. The difficulty in choosing
between the variants is due to the absence of a ‘gold
standard’. While continuous scientific explorations are
warranted to inform future choices about valuation tech-
niques, the need for comparability suggests that standard-
ization of the tasks used in valuation protocols is desirable.
Analogous to the ‘reference case’ approach proposed by
the US panel on cost-effectiveness on health and medicine
[8], standardization can ensure the comparability of dif-
ferent studies and therefore consistent decision making.
Among currently available protocols, those developed
by the EuroQol Group (http://www.euroqol.org) are the
most widely studied and utilized. The EuroQol Group first
met in 1987 to test the feasibility of jointly developing a
standardized generic instrument for describing and valuing
health-related QOL (HR-QOL). From the outset, the
EuroQol Group has been multi-country, multi-centre,
multi-disciplinary and not for profit. Over several years, the
EuroQol Group developed a generic HR-QOL instrument,
called the EQ-5D [9, 10]. It uses a standardized health state
descriptive system consisting of five dimensions: mobility,
self-care, usual activities, pain/discomfort and anxiety/de-
pression, each of which has three levels of severity. Since
then, two additional versions of the EQ-5D have been
created: the EQ-5D-Y, for use in children and adolescents
aged 8–15 years [11]; and the EQ-5D-5L, with five
severity levels per dimension [12]. In this paper, we refer to
the original (3-level) version of EQ-5D as EQ-5D-3L.
In addition to the instruments, the EuroQol Group has
also developed protocols for valuation of health states
defined by its instruments. Three of these valuation pro-
tocols included TTO as the main valuation task: the Mea-
surement and Valuation of Health (MVH) protocol [13];
the so called ‘Paris’ protocol [14] and the EuroQol Valu-
ation Technology (EQ-VT) protocol [15]. All three proto-
cols focus on the data-collection procedure using TTO.
Because the EQ-5D and the TTO-based valuation studies
are used in many different countries, the protocols do not
include requirements for sampling frameworks or for
modelling the collected TTO data, as these can vary by
country. In addition, experimental design aspects, such as
the algorithm for the selection of the health states in TTO
experiments, are not part of the EuroQol Group’s valuation
protocols.
The purpose of this paper is to provide a detailed
introduction and critique of the three valuation protocols
developed by the EuroQol Group focusing on TTO data
collection, and to provide recommendations for their usage.
We start with an overview of the different variants of the
TTO that have been included in the EuroQol Group’s
protocols and their most important characteristics. We then
describe the three EuroQol valuation protocols. We con-
clude by discussing research that may help further improve
the current EuroQol protocols.
2 The Time Trade-Off (TTO) Tasks
The objective of the TTO is to determine the length of life-
time the respondent would be willing to forego to live in a
better health state (typically ‘full health’) and avoid living
in a bad health state. This is achieved by presenting
respondents with a series of choice tasks, each involving
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two alternative hypothetical lives. The two lives are pre-
sented such that the respondent is forced to choose between
a longer life in the health state of interest and a shorter life
in better health. Depending on which life is chosen, the
amount of time in better health is altered until a point of
preferential indifference is reached. This constitutes the
basic framework of all TTO tasks. However, the described
framework can be implemented in a variety of ways. TTO
implementations may differ in trade-off framework, itera-
tion procedure and its mode and method of administration,
training of respondents and interviewers and quality con-
trol of data collection.
2.1 TTO Frameworks
2.1.1 Conventional TTO
In conventional TTO (also referred to as classic or tra-
ditional TTO), health states considered better or worse
than death are valued using different approaches. For an
impaired state h, which is considered better than death
(BTD), the respondent faces a series of choices between
two hypothetical lives: one involving x years of healthy
life, followed by death (alternative 1); the other involving
t years in h (where x B t), followed by death (alternative
2). Time t is fixed, whereas time x is varied until the
respondent’s point of indifference is identified. If the
respondent prefers alternative 2 to alternative 1, x is
increased to make alternative 1 more attractive; if the
respondent prefers alternative 1 to alternative 2, x is
reduced to make alternative 1 less attractive. This itera-
tive procedure continues until the respondent is unable to
choose between the two lives. The value of h, U(h), is
calculated according to how much healthy time the
respondent is willing to forgo at this point of indifference,
and is given by x/t. This is shown schematically in
Fig. 1a.
In conventional TTO, if h is considered by the respon-
dent to be worse than death (WTD), the respondent is
presented with a different type of choice: between a life
involving t - x years in h, followed by x healthy years and
then death (alternative 1); and immediate death (alternative
2). The value of x is varied until the respondent’s point of
indifference is identified, at which point the U(h) = -x/
(t - x). This is illustrated in Fig. 1b. As can be seen, the
approaches used to value health states BTD and WTD are
fundamentally different. The use of different approaches to
produce values on a single scale has been a major point of
critique for the conventional TTO [16]. A second point of
critique for the conventional TTO is that the scale has an
upper bound of 1 but a lower bound of negative infinity if
all time x is traded off in the WTD procedure. While the
BTD and WTD procedures are visually similar, the value
of the health state U(h) in the BTD procedure is a linear
function of the length of life in full health (x), whereas a
(visually similar) change in the WTD procedure involves
changing both the length of life in h and the length of life in
full health, such that U(h) is a rapidly steepening function.
Three types of solutions have been proposed to deal with
this scale issue: rescaling the WTD values to a scale
ranging from 0 to -1 [17–19]; changing the measure of
central tendency from the mean to the median [19, 20]; and
using geometry-based (angular) methods [21]. The choice
of method for handling WTD values has been shown to
have a substantial impact on the resulting values [19, 22].
A thorough discussion of the relative merits of these pro-
cedures is beyond the scope of this paper, but all of them
have been criticized for having limited theoretical under-
pinnings [21, 22].
2.1.2 Composite TTO
Robinson and Spencer [16] proposed an alternative
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Fig. 1 Conventional time trade-off. h impaired health state, U(h) value of state h, x time in full health, t time in state h
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BTD and WTD values: lead-time TTO. This approach
involves adding healthy life-years (‘lead time’; l) before
both of the lives being compared in the BTD task of con-
ventional TTO (Fig. 2a). This allows the respondent to
trade off these additional years when he or she considers
h to be WTD (Fig. 2b). Research conducted using lead-
time TTO showed severe framing effects and made clear
that respondents had difficulties with the task. One finding
was that it was not clear to respondents that trading into the
lead time implied that the health state was considered to be
worse than death [15, 23, 24]. The composite TTO was
proposed as a compromise between the conventional TTO
and lead-time TTO [25]. For health states BTD, the BTD
task of the conventional TTO is used, while for health
states WTD, lead-time TTO is used. This makes the dis-
tinction between BTD and WTD explicit to respondents,
compared with lead-time TTO, and makes the BTD and
WTD tasks more comparable than with conventional TTO.
The value of h for BTD is calculated according to the
conventional TTO, U(h) = x/t (x B t) (Fig. 1a). The value
of h for WTD is calculated according to lead-time TTO,
U(h) = (x - l)/t (x B t ? l) (Fig. 2b). As with conven-
tional TTO, composite TTO can be criticized for eliciting
BTD and WTD values through different procedures, but
the switch of WTD procedure to more closely resemble the
BTD procedure is believed to be an improvement over
conventional TTO [25].
2.2 Iteration Procedures and Mode and Method
of Administration
2.2.1 Iteration Procedures
The variation of the length of life in alternative 1 (the
x value) requires the determination of a starting point, an
iteration algorithm and a termination rule (on what condition
to end the iteration process). The starting point can be a
fixed or random value, whereas the iteration algorithm and
the termination rule are usually standardized for all
respondents. Most iteration algorithms can be described as
being in one of three categories: titration, in which the
length of life is sequentially altered by fixed increments/
decrements; bisection, in which the length of life is always
the midpoint of the remaining scale section (bisected); or
‘ping-pong’, where high and low values are alternately
presented [6]. Combinations of different iteration procedures
can also be used, for instance starting with a few steps of bi-
section, followed by titration. The rule for termination can
be the identification of the indifference point or the bound-
aries of a range surrounding the indifference point.
2.2.2 Mode and Method of Administration
Traditionally, one-on-one personal interviews have been
used for the collection of TTO data. Nowadays, due to
developments in technology, online data collection has
become very popular, as it can substantially reduce the
costs of conducting a valuation study. Studies conducted by
the EuroQol Group on the impact of administration mode
on TTO data collection showed that group-based inter-
views and online data collection resulted in a substantially
larger proportion of respondents stating their point of
indifference after just one or two steps in the iteration
procedure than one-on-one personal interviews [15, 26–
28]. Because this is a clear indicator for a reduction in task
comprehension and/or engagement of the respondents, the
recently developed EuroQol protocols continue to be based
on one-on-one personal interviews.
Before the digital age, a TTO time board was used by
interviewers to guide respondents through the iterative
procedure. Computer technology can be used to make TTO
tasks easier to administer. For example, computer-assisted
personal interviewing (CAPI) can help ensure more con-
sistent interview conditions and protocol compliance by
automatizing the iteration procedure and minimizing vari-
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Fig. 2 Lead-time time trade-off. h impaired health state, U(h) value of state h, x time in full health, l lead time, t time in state h
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risk of coding errors, as there is no need to enter the
obtained data into a database that is needed for analyses.
2.2.3 Visual Aids
The concept of TTO (i.e. trading-off QOL and length of
life) may not be straightforward to individuals from whom
preferences are to be elicited. The iteration procedures used
to search for TTO values add to the complexity of the task.
To improve task comprehension and conduct of the TTO
tasks, visual aids in the form of TTO time boards are
usually used in TTO-based valuation studies. In general,
the visual aids take the form of graphs or props and use
straight lines or graduated scales to illustrate the length of
the different lives. The design of the visual aids and their
use by the interviewers supports illustration of the variation
of the length of lives so the iteration procedure can be
followed by respondents without confusion. In a CAPI
setting, digital versions of the TTO time boards are typi-
cally used instead of physical props.
2.3 Warm-Up Tasks for Respondents
TTO is difficult in that respondents need to understand the
rather abstract concept of a ‘health state’, the difference
between QOL and length of life, and the concept of trade-
offs. The task is further complicated by requiring the
respondent to imagine hypothetical health states of which
many have no prior experience, over time horizons that
may be unrealistic or difficult to contemplate. To prepare
the respondents for TTO tasks, warm-up tasks and training
of respondents such as a simple example or exercise are
typically conducted before respondents are asked to
embark on the formal valuation tasks. They can also help
identify respondents who are unable to understand TTO
tasks.
2.4 Training for Interviewers
Health state valuation is difficult not only for the respon-
dent but also for the interviewer. Interviewers must be able
to explain all aspects of the task to respondents. The pre-
specified iteration procedure the interviewer is required to
use may be complex. In such a setting, the interviewer can
unwittingly (or deliberately) influence responses through
idiosyncratic application of the interview protocol. Sup-
porting materials such as a thorough interviewer script,
visual aids and response recording sheets or standardized
software can help to mitigate interviewer effects. Training
of interviewers aims to familiarize them with the study
protocol and reduce the potential for interviewer effects. A
multiday training workshop is recommended, covering the
study background and objectives, detailed discussion of the
interviewer script, and opportunities for demonstration,
practice and feedback.
2.5 Quality Control of Data Collection
Quality control is an important element in TTO-based
valuation studies. The purpose is to ensure protocol
adherence to the extent that interviewers properly explain
the aim and all elements of the task, mitigating interviewer
effects. Measures for quality control should focus on
interviewer behaviour. The measures should include eval-
uation of protocol proficiency and examination of inter-
view times invested in each task (a proxy indicator of
thoroughness). In addition, the measures should aim to
evaluate respondents’ comprehension of and engagement
in the TTO tasks. All TTO-based studies should include
this component. This is nowadays typically included in
clinical trials [29], but—to our knowledge—not in valua-
tion studies. The EuroQol Group now integrates it in all
computer-based TTO valuation studies.
3 The EuroQol Valuation Protocols
Table 1 summarizes the main characteristics of the three
protocols. The MVH and Paris protocols were developed in
sequence for valuation of the EQ-5D-3L health states using
conventional TTO. These protocols reflected the state of
the art in TTO-based valuation at the time (1993 and 2009,
respectively). The EQ-VT protocol is built on the experi-
ence obtained from the earlier protocols and on a set of
multinational pilot studies [15]. It was launched in 2012.
All three protocols feature warm-up exercises to familiar-
ize the respondent with the EQ-5D health states and the
TTO technique. In all three protocols, the respondent is
first asked to classify their own health with EQ-5D to
introduce them to the concept of health states. In the MVH
and Paris protocols, the respondent is then asked to rank a
set of health states and then to value these using a VAS. In
the EQ-VT protocol, the warm-up tasks do not involve
ranking or VAS valuation, but focus on practicing the
valuation of health states using composite TTO prior to
formal valuation tasks. All three protocols feature study
designs capable of providing the necessary data for mod-
elling using a multitude of regression techniques. For
example, all three require each respondent to value ten or
more different health states using TTO, allowing for indi-
vidual-level models such as random-effects models. In
addition, all protocols include a second valuation tech-
nique. The MVH and Paris protocols use VAS valuation
prior to the TTO task, whereas the EQ-VT protocol
includes a DCE after the TTO tasks [15]. For the purposes
of this paper, we concentrate on the trade-off framework,
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iteration procedure and its mode and method of adminis-
tration, training and quality control measures when
describing the EuroQol protocols.
3.1 The MVH Protocol
The MVH protocol was developed in 1993 for eliciting the
utility values of EQ-5D-3L health states from a general UK
population sample [13]. The conventional TTO using a
fixed time horizon of t = 10 years was adopted. The two
anchor states used are the best health state defined by EQ-
5D-3L (health state ‘11111’, i.e. no problems in any of the
five dimensions) and immediate death. The iteration pro-
cedure of the MVH protocol uses a mix of three algo-
rithms: bisection for the first three steps followed by an
upward/downward titration procedure. The respondent is
first asked to choose between 10 years in 11111 (life A)
and 10 years in the target state (life B). Second, he or she is
asked to choose between 0 years in good health (life A),
i.e. immediate death, and 10 years in the target state (life




Framework Conventional TTO Composite TTO
Anchor states 11111 (‘no problems in walking about; washing or dressing oneself; and
performing usual activities; no pain or discomfort; not anxious or depressed’)
and ‘death’
‘Full health’ and ‘death’






For BTD states: Life A—living in full health for x years followed by death
(alternative 1); Life B—living in the impaired state for 10 years followed by
death (alternative 2)
For WTD states: Life A—living in the impaired state for 10 - x years, then full
health for x years followed by death (alternative 1); immediate death
(alternative 2)
For BTD states: Life A—living in full
health for x years followed by death
(alternative 1); Life B—living in the
impaired state for 10 years followed by
death (alternative 2);
For WTD states: Life A—living in full
health for x years followed by death
(alternative 1); Life B—living in full
health for 10 years, then the impaired
state for 10 years followed by death
(alternative 2)






Bisection for the first three steps followed
by upward/downward titration with
1-year increments and a correction of
6 months when preference reversal
occurs
Bisection for the first three steps
followed by upward/downward
titration with 1-year increments
without any correction
Bisection for the first three steps followed
by upward/downward titration with
1-year or 6-month increments and






range = 6 months
Indifference/indifference









Paper-and-pencil with a time board as the visual aid Electronic data collection and digital
presentation of the visual aid
Training and quality control
Respondent
training
Ranking and VAS-based warm-up tasks plus explanation of TTO by interviewer One example and three practices
Interviewer
training
Interviewer training workshop (unstandardized) Interviewer training workshop
(unstandardized)
Quality control No quality control procedure was formalised and included in the protocol Standardised quality control software
BTD better than death, EQ-VT EuroQol valuation technology, MVH measurement and valuation of health, TTO time trade-off, VAS visual
analogue scale, WTD worse than death
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B). Depending on the choice in the second task, the length
of life A uses the mid-point of the BTD or the WTD scale
(5 years in both cases) in the third task.
Following the third choice, the procedure continues
with 1-year incremental changes to life A, followed by a
6-month correction at preference reversal. If life B is
considered BTD, the third choice will compare 5 years
in full health (life A) with 10 years in the target state
(life B), followed by one-year adjustments. If x denotes
the length of life A at the point of indifference, the
value of the target state h is calculated as U(h) = x/10.
If life B is considered WTD, a different task is pre-
sented. In this case, the respondent is faced with a
choice between a composite life A, which begins with
t - x years in the target state h, followed by x years in
‘11111’, for a fixed total of t = 10 years, and a life B of
0 years (immediate death). In the third choice question,
life A is described as 5 years in h, followed by 5 years
in ‘11111’. If life A is preferred, life A will be altered
to 6 years in h, followed by 4 years in ‘11111’. If life B
is preferred, the time in h will be decreased to 4 years,
followed by 6 years in ‘11111’. If 10 - x is the number
of years in the WTD state, and x is the number of years
in full health, the value of the target state is U(h) = –x/
(10 - x) when indifference is achieved. The iteration
terminates when the respondent states preferential
indifference, or when the point of indifference could be
inferred to lie between two life ‘A’s differing by
6 months in length, at which the mid-point is assumed
to be the point of indifference. The full iteration
scheme is illustrated in Appendix Fig. 5a.
The MVH protocol is designed for use in one-on-one,
face-to-face interviews. A data-collection form incorpo-
rated with step-by-step instructions and a standardized
script [30] is prepared for trained interviewers to strictly
follow the above-mentioned elicitation technique. A spe-
cially designed visual aid called a ‘time board’ is prepared
for the interviewer to present the anchor and target states
and explain the valuation tasks. As illustrated in Fig. 3,
there are two horizontal graduated bars on side A of the
time board representing the two hypothetical lives for
valuing BTD states; a similar bar with two sections on side
B is used to illustrate life A for valuing WTD states. All
health states are presented by attaching cards to the time
board, and the different lengths of life A are presented
using a sliding pointer. The MVH protocol includes neither
specific quality control components nor training guidelines
for interviewers.
Fig. 3 The visual aids used in
the MVH and Paris protocols.
a Visual aid for valuation of
states considered to be better
than death; b visual aid for
valuation of states considered to
be worse than death. MVH
measurement and valuation of
health
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As stated previously, there are many different options
with respect to the details of the TTO. All of these have
their own pros and cons. Since there is no ‘gold standard’
for valuation, it is unavoidable that, when designing a TTO
protocol, some decisions are not based on empirical evi-
dence, such as the decision to use a fixed 10-year time
horizon.
Several issues of concern became apparent from the use
of the MVH protocol, including within-respondent logical
inconsistency in valuation [31, 32], great variance among
respondents [18, 33], interviewer effects [33] and a non-
continuous value distribution [18, 33, 34]. Also, it should
be noted that the MVH protocol was not officially stan-
dardized or recommended. Many studies used MVH-like
protocols that were similar but not identical, thus ham-
pering the comparability of the resultant value sets. TTO-
based valuation studies using these protocols are reviewed
elsewhere [35].
3.2 The Paris Protocol
The Paris protocol is an updated version of the MVH pro-
tocol for valuation of the EQ-5D-3L health states, refined to
improve the data-collection process [14]. The main differ-
ence between the two protocols is that the Paris protocol uses
a simplified iteration procedure and a different selection of
health states. In the Paris protocol, iteration is terminated
either when indifference is stated or, if indifference is not
stated, when the interval surrounding the indifference point
is narrowed to 1 year. This means that only integer years are
used as x values in the iteration procedure. As illustrated in
Appendix Fig. 5b, the number of x values is half of that for
the MVH protocol. Accordingly, the interview and the data-
collection forms are less complex than those of the MVH
protocol. The rationale for using the simplified iteration
procedure is to improve efficiency. Increasing the unit of
measurement from 6 months to 1 year would not be expec-
ted to have amajor effect on themean and standard deviation
of observed values for health states given the wide variations
in values across individual respondents.
The Paris protocol has been used in a number of EQ-5D-
3L valuation studies [36–40] since being proposed in 2009,
but we are not aware of any empirical research on the
comparative merits of the Paris and MVH protocols.
3.3 The EQ-VT Protocol
The EQ-VT protocol adopts the composite TTO. The iter-
ation procedure is built on that of the MVH protocol: initial
comparison to 10 years in full health, separation into BTD/
WTD, bisection of the BTD/WTD scales, and 1-year
incremental adjustments followed by a 6-month correction
at preference reversal. Unlike the MVH and Paris protocols,
the composite TTO task does not terminate until the
respondent states indifference, allowing endless adjustments
by 1-year increments, followed by 6-month corrections
whenever the direction of preference is reversed. The EQ-
VT protocol also allows easy variation of the x values within
and across the BTD/WTD scales. The possible utility value
ranges from -1 to 1, with the smallest difference between
values being 0.05 (see Appendix Fig. 5c).
The EQ-VT protocol is designed for use in computer-
assisted personal interviews. A visual aid similar to those in
the MVH protocol is presented on the screen to illustrate the
composite TTO questions (Fig. 4). All components of the
protocol, including an interviewer guide, were developed to
provide standardized interview conduct. Multiple training
and quality control components are included in the EQ-VT
protocol. First, a recommended interviewer-training proce-
dure has been developed. Second, a training task is incor-
porated into the interview to make sure the respondent
understands the concept of TTO. The interviewer first shows
how TTO works using as an example the state of being ‘in a
wheelchair’. This training task is followed by three practice
tasks where the respondent is asked to value EQ-5D-5L
health states of varying severity of problems.
The EQ-VT protocol was informed by a multi-country,
multi-stage research program [41]. Two major aspects of
the design in the EQ-VT protocol were based on empirical
research. The composite TTO was adopted after scientific
investigation of several TTO variants, including conven-
tional TTO, lead-time TTO and lag-time TTO [27], using
differing visualizations and time horizons. Furthermore,
the decision to use face-to-face interviews was made after
testing internet surveys and group interviews [28]. Empir-
ical studies were also conducted to inform decisions on
other aspects of the protocol design such as the visual aid
[26] and the anchor state ‘full health’ [42].
A number of EQ-5D-5L valuation studies have used the
EQ-VT protocol since its first version (version 1.0) became
available in 2012. While those studies showed that the
protocol is feasible, reliable and sensitive to variations in
EQ-5D-5L health states, some issues have also emerged.
Protocol adherence by the interviewers and data distribu-
tion were two areas worthy of attention. Analyses of
interviews performed using the protocol indicated the
presence of interviewer effects, with respect to both pro-
tocol compliance and TTO values obtained [43]. To
address these issues, quality control software (QC tool) was
developed and implemented in the second version of the
protocol, which allows for real-time monitoring of protocol
compliance and interviewer performance from the start of
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interviewer training and during the entire data-collection
process. Interviewers failing to follow the protocol can be
identified and retrained during data collection or removed
from the study.
As stated previously, the EQ-VT includes a DCE in
addition to the TTO task. When the development of the
EQ-VT started, it was recognized that TTO as a valuation
technique has its limitations and that other valuation
techniques might be needed to replace or to be used in
conjunction with TTO to make the valuation studies more
affordable and feasible. Based on the promising results of a
pilot study [44], DCE, which is rooted in random utility
theory, became one of the main candidates. In a DCE,
respondents are shown multiple (usually two) EQ-5D
health states and asked to indicate which one they prefer,
arguably making the valuation task easier to understand for
respondents than TTO. However, this reduction in task
complexity comes with a cost: health state values based on
DCEs are on an arbitrary scale based on the relative dis-
tances between health states and not on a scale anchored at
0 (death) and 1 (full health) as is required by the QALY
model. Until this anchoring problem is properly resolved,
DCE as a standalone technique is not viable for generating
utilities for use in QALY calculations and therefore cannot
replace the TTO.
However, both DCE and TTO attempt to measure the
same concept in different ways and both types of data seem
to contain information relevant to this concept (i.e. the
utility function). Therefore, the data resulting from the two
elicitation techniques could be seen as complementary
rather than competing. Put another way, the assumption is
that respondents have a unique utility function that gener-
ates both types of responses. This leads to the idea of
combining the TTO and DCE data into a single modelling
framework: the hybrid model. The hybrid model is a
maximum likelihood model where the ‘hybrid likelihood’
is the product of the likelihoods of the TTO data and the
DCE data. The b’s of the TTO model and those of the DCE
model are connected via a link function to account for the
differences between the scales [43]. A hybrid model
maximizes the use of the available data from a valuation
study using the EQ-VT protocol.
4 Ongoing and Future Research
Given the nature of health state values, it will never be
possible to determine if or when a valuation method has
reached perfection. Thus, the EQ-VT protocol, represent-
ing the current state of the art of the EuroQol Group’s
TTO-based valuation methods, is undergoing continuous
scientific investigation for ways to further improve its
performance and user friendliness [45]. Some of the
research ideas that are currently being investigated or may
be implemented in the future are briefly described below.
These involve testing alternative iteration procedures and
time horizons used in the composite TTO, as well as
comparison with other TTO valuation protocols.
Several of the challenges associated with TTO are tied to
the iteration procedure. The sequential change of lengths of
the presented lives can be difficult to explain and under-
stand, and when exposed to an adaptive sequence of choices,
Fig. 4 The visual aids used in the EQ-VT protocol. a Visual aid for
valuation of states considered to be better than death; b visual aid for
valuation of states considered to be worse than death. EQ-VT EuroQol
valuation technology
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respondents can develop response strategies that result in
biased values. Thus, the development of a TTO or TTO-like
valuation procedure that does not rely on iteration might be
beneficial for the EuroQol valuation protocols.
The chosen time horizon is likely to influence resulting
TTO values [46, 47]. The choice of a 10-year horizon has
not been explored to a great extent in any of the three
EuroQol protocols. Hence, further research is warranted to
test alternative time horizons for the EuroQol valuation
protocols, especially in light of the assumption of constant
proportional time preference. Both fixed and variable time
horizons may be worth testing. Since shorter timespans
may be more plausible for certain health problems, since it
is unlikely that patients are left in such states for a long
time in clinical practice, shorter time spans could merit
further investigation. Also, a life expectancy of 10 years
may be unrealistic for certain respondents such as the
elderly or patients with severe conditions [48]. However,
the use of a short time horizon may create the issue of non-
equivalence in resultant utility values with the current time
horizon. When investigating this issue, attention should be
paid to the effect of time horizon on severe health states, as
some evidence suggests a maximum endurable time may
exist for such states [49].
Last but not least, it would be beneficial to compare the
performance of the EuroQol protocols and TTO valuation
protocols developed outside the EuroQol Group. The TTO
technique has been widely used to elicit utility values of
health states not described by the EQ-5D. Although the
valuation protocols used in those studies were not tested as
thoroughly as the EuroQol protocols, some aspects of their
design may be superior. A systematic review of the cur-
rently available TTO protocols and head-to-head compar-
isons of promising protocols with the EuroQol protocols in
valuation of EQ-5D health states could provide valuable
clues for how to further improve the EuroQol protocols.
5 Concluding Remarks
The EuroQol protocols provide standardized approaches to
valuing EQ-5D health states using the TTO technique.
These protocols are products of decades of research and
development by an international group of multi-disci-
plinary researchers and they form an important basis for the
current practice of health technology assessment in many
countries. Hence, it is important for health researchers and
policy makers to understand these protocols and to further
improve them.
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